Is AstraZeneca a Buy as It Eyes the Weight Loss Market?

Medications used to treat diabetes and obesity are the hottest commodities in healthcare right now. Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have all become blockbuster drugs, and their momentum doesn't seem to be going away.While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies are looking to enter the space. Earlier this month, British pharma leader AstraZeneca (NASDAQ: AZN) announced some encouraging data on its own obesity drug candidates.Let's dig into the situation at AstraZeneca, and explore whether this is a good opportunity to buy the stock, as the company sets its sights on healthcare's next big renaissance.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool